EUVIMEDEUVIMED entdecken
Crossref

Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases

Mingxi Lin, Yizi Jin iD, Hong Lv, Xichun Hu, Jian Zhang iD

International Journal of Cancer · 2023-04 · 152 (7) · 1476-1489

DOI: 10.1002/ijc.34365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 30.11.2022. Verfasst von Mingxi Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Bone Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ER, PgR and HER‐2 status are the cornerstones of choosing systemic therapy for breast cancer, but can change during the disease course. Guidelines recommended the biopsy of the metastatic tumor to reassess receptor status. Bone is the most frequent metastatic site of breast cancer but remained technically difficult to biopsy. Our study aimed to evaluate the incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. One hundred and fifty‐five breast cancer patients were diagnosed with pathology‐confirmed bone metastasis at Fudan University Shanghai Cancer Center. Ninety‐three patients with receptor status available on both primary tumor and bone metastases were included in our study. ER, PgR and HER‐2 status converted from positive to negative in 10.8% (10/93), 28.0% (26/93) and 8.6% (8/93) of the patients, while ER, PgR and HER‐2 status converted from negative to positive in 3.2% (3/93), 4.3% (4/93) and 1.1% (1/93) of the patients, respectively. 40.4% (17/42) of the HER2‐0 tumors converted to HER2‐low, which enabled them to receive the treatment of new antibody‐drug conjugates (ADCs). Prior endocrine and anti‐HER2 therapy were the independent risk factors for receptor conversion. Loss of HR expression in bone metastases was significantly associated with worse first‐line PFS (adjusted hazard ratio = 3.271, P ‐value = .039) and OS (adjusted hazard ratio = 6.09, P ‐value = .011). In conclusion, our study confirmed that patients may experience receptor conversion between primary breast cancer and bone metastases, possibly influenced by prior treatments, which significantly influenced prognosis. The rebiopsy of bone metastases in patients with primary HER2‐0 tumors may benefit from the new ADC drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBone NeoplasmsHumansFemalePrognosisBiomarkers, TumorIncidenceChinaErb-b2 Receptor Tyrosine KinasesReceptors, Progesterone

Stichwörter der Autor:innen

biopsybone metastasesbreast cancerprognosisreceptor conversion

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesReceptors, Progesterone

Autor:innen und Institutionen

  • Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.

ORCID-Profile: Yizi Jin, Jian Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lin, M., Jin, Y., Lv, H., Hu, X., & Zhang, J. (2023). Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. International Journal of Cancer, 152(7), 1476-1489. https://doi.org/10.1002/ijc.34365

Vancouver

Lin M, Jin Y, Lv H, Hu X, Zhang J. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases. International Journal of Cancer. 2023;152(7):1476-1489. doi:10.1002/ijc.34365

BibTeX
@article{Lin2023,
  author = {Lin, Mingxi and Jin, Yizi and Lv, Hong and Hu, Xichun and Zhang, Jian},
  title = {Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases},
  journal = {International Journal of Cancer},
  year = {2023},
  volume = {152},
  number = {7},
  pages = {1476--1489},
  doi = {10.1002/ijc.34365}
}
Kostenlos starten →